ASTROCYTOMA, IDH-MUTANT, GRADE 2
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for brain tumor patients when standard drug fails
Disease control Not yet recruitingThis study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Targeted pill aims to stall a common brain Tumor's growth
Disease control Not yet recruitingThis study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiat…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC